- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03020225
Protein Bioavailability of Wolffia Globosa (Mankai); Acute Test Meal Effects (Mankai)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators aim to test the protein bioavailability of new specific developed strain of duckweed [Wolffia globose, Mankai], an aquatic plant, which might serve as a protein source and contains all the 9 essential and the 6 conditional amino acids. "Mankai" [(Generally recognized as safe (GRAS)] is a cultivated strain of Wolffia globosa, which is an aquatic plant, part of the family of plants known commonly as duckweeds. Duckweeds are very simple flowering aquatic plants which float on or just beneath the surface of still or slow-moving bodies of water. There is a long history of the use of Wolffia species, in particular Wolffia Globosa, as food, especially in Southeast Asia: Burma, Laos and northern Thailand, where it has been used as a vegetable for many generations. There are numerous ways of W. globosa consumption and a variety of recipes, using it either as a main ingredient (such as Wolffia crisps or "kaeng pum" - a popular vegetable dish in northeastern Thailand) or incorporating it in other foods (e.g. Wolffia-meat ball, fermented Wolffia-meat sausage, Wolffia rice noodle, Wolffia cookies, Wolffia bread, and various soups and salads). Along with its long history as a food source in Southeast Asia, it is recognized as an edible vegetable for humans in several databases, including the United States Department of Agriculture (USDA 2014) GRIN database and a database dedicated to tropical species. The nutritional composition of Mankai has been determined and found to be high in protein, containing all the essential and conditionally essential amino acids, dietary fibers and several vitamins and minerals. In a recent safety study, which aimed to test the safety of Mankai administration within and 3 times of the amount approved in the GRAS, 4 groups of female SD rats were orally administered for 4 consecutive days a daily dose of Mankai at three dose levels of 1700, 2500 and 3400mg/kg of Mankai, equivalent to 20, 40 and 60 gr/day human dose, respectively. Clinical (e.g body weight, food intake, morbidity/mortality, toxic signs), pathological (post mortem gross pathology examination) and long list of blood biochemical indicators (e.g liver status biomarkers, stress indicators, minerals) did not show any adverse effects. The results indicate that repeated four day Mankai administration did not cause adverse effects. Unexpectedly, high doses even suggested beneficial results with anti-glycemic effects. Mankai was found to have a high digestibility profile (89%) according to Protein digestibility-corrected amino acid score (PDCAAS) Eurofins tests. However, its human nutrient bioavailability has not been examined yet. For the proposed test, Mankai (grown by Hinoman Ltd., Israel) will be provided as a fresh, whole, product.
Methods: 36 men will be randomized to consume the following food items, which will be equivalent to 30gr protein, after 12h night fasting:
- Reference group: animal protein food source: White cheese, intact, plus 250ml mineral water
- Test group 1: plant food source: Green peas, intact, cooked, plus 250ml mineral water
- Test group 2: plant food source: Wolffia globosa (Mankai), intact, cooked, plus 250ml mineral water
The participants will be asked to maintain a stable diet (according to guidelines that will be provided) for 3 days prior to the test meal. Blood samples will be taken at times 0, 30, 90, and 180 minutes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dimona, Israel
- nuclear research center Negev
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age >30 years; abdominal adiposity (waist circumference: men > 102 cm, women > 88 cm) or dyslipidemia
Exclusion Criteria:
- triglycerides>400 mg/dL; serum creatinine>2 mg/dL;
- disturbed liver function;
- pregnant or lactating women;
- presence of active cancer, is receiving or received chemotherapy in the last three years; participation in another trial;
- participants who are treated with Coumadin (warfarin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: White cheese
Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
|
animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
|
|
Experimental: Green peas
Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
|
Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
|
|
Experimental: Mankai
Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
|
Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amino Acid Profile (Blood Biomarkers)
Time Frame: 3 hours
|
will be analysed by metabolomic for amino acid profile (trajectory)
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic Profile
Time Frame: 3 hours
|
glucose (blood biomarkers)
|
3 hours
|
|
Lipid Profile
Time Frame: 3 hours
|
HDL cholesterol fractions (blood biomarkers)
|
3 hours
|
|
Liver Function
Time Frame: 3 hours
|
ALT (blood biomarkers)
|
3 hours
|
|
Minerals
Time Frame: 3 hours
|
potassium (blood measures)
|
3 hours
|
|
Vitamins
Time Frame: 3 hours
|
B12 (blood measures)
|
3 hours
|
|
Glycemic Profile-Insulin
Time Frame: 3 hours
|
Insulin (blood biomarker)
|
3 hours
|
|
Triglycerides
Time Frame: 3 hours
|
Triglycerides levels- Lipid profile
|
3 hours
|
|
Liver Enzymes- ASAT
Time Frame: 3 hours
|
ASAT - Liver enzymes
|
3 hours
|
|
Magnesium
Time Frame: 3 hours
|
Magnesium levels
|
3 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shai, Ben-Gurion University of the Negev
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BenGurionU
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Men With Mild Abdominal Obesity
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedPeople Living With HIV | Men Who Have Sex With MenFrance
-
National Research Council, SpainMinisterio de Economía y Competitividad, SpainCompletedSubjects With Abdominal ObesitySpain
-
University of MiamiNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingHIV Prevention | Pharmacy | Latino Men Who Have Sex With MenUnited States
-
University Hospital, MontpellierWithdrawnMen Having Sex With Other Men
-
Leonard S. Marks, M.D.Watson Pharmaceuticals; Solvay PharmaceuticalsCompletedMen With Low Testosterone LevelsUnited States
-
VA Office of Research and DevelopmentCompletedOlder Men and Women With High Fall RiskUnited States
-
Andrew CarrCompletedHIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With MenAustralia
-
National Taiwan University HospitalUnknownAbdominal Obesity Metabolic Syndrome | Subjects With Poor Fitness StatusTaiwan
-
Thai Red Cross AIDS Research CentreUnited States Agency for International Development (USAID)CompletedMen or Transgender Women Who Have Sex With MenThailand
-
Corporacion Parc TauliCompletedHealthy Men | Healthy Women | Women With Recent Diagnosis of Schizophrenia | Men With Recent Diagnosis of SchizophreniaSpain
Clinical Trials on White cheese
-
Hospices Civils de LyonCompletedCardiometabolic RiskFrance
-
University of TorontoDairy Farmers of CanadaCompletedObesity | DiabetesCanada
-
Anne Birgitte RabenUniversity of Aarhus; Arla FoodsCompleted
-
University of CopenhagenThe Danish Dairy Research Foundation, Denmark; National Dairy CouncilUnknown
-
Norwegian University of Life SciencesTineCompleted
-
MeddocNorwegian School of Sport SciencesCompletedBone Health | Performance Enhancing Product UseNorway
-
University of CopenhagenDairy Farmers of Canada; The Danish Dairy Research Foundation, Denmark; Dairy... and other collaboratorsCompletedMetabolic SyndromeDenmark
-
MeddocTine; Norwegian University of Life SciencesCompletedOsteocalcin | Vitamin K Deficiency | Maintenance DoseNorway
-
University of CagliariRecruiting
-
University of LeedsAlmond Board of CaliforniaCompletedHyperphagia | Lack of Satiety